Eczema Treatment — XTRAC Excimer Laser

XTRAC 308 nm excimer laser treatment for eczema targets the T-lymphocytes driving atopic, contact, seborrheic and dyshidrotic dermatitis, suppressing the inflammatory cascade without the need for prolonged corticosteroid application. The narrow-band UV laser is applied precisely to affected skin zones only — unlike topical or systemic treatments that affect the whole body — with a course of ten to twenty sessions suppressing symptoms over months. At Derma Medical Clinic XTRAC eczema treatment is offered as an alternative or adjunct to conventional therapy, with particular relevance for patients seeking to reduce long-term steroid exposure.

Eczema (atopic dermatitis and its related conditions) is characterised by a dysregulated immune response in which T-helper lymphocytes over-activate, triggering the release of cytokines that cause epidermal barrier disruption, intense itching, inflammatory redness and lichenification. The different eczema subtypes — atopic dermatitis (the most common), contact dermatitis, seborrheic dermatitis and dyshidrotic dermatitis — share this T-lymphocyte-driven inflammatory mechanism, which is why they all respond to the same laser wavelength. The XTRAC 308 nm excimer laser used at Derma Medical Clinic delivers narrow-band UV energy selectively to the affected skin patches. At the cellular level, 308 nm radiation induces apoptosis in the activated T-lymphocytes resident in the inflamed lesions, breaking the cytokine cascade that sustains the itch-scratch cycle and the epidermal barrier disruption. Because the laser is applied only to affected zones, surrounding healthy skin is not exposed — a significant advantage over systemic or whole-body UV phototherapy approaches. A standard eczema treatment course consists of ten to twenty sessions, with one to two sessions per week depending on the severity of involvement and the treatment area. Sessions themselves are brief — a few minutes for localised lesions — and the sensation is typically described as mild warmth. A notable clinical advantage of XTRAC for eczema is that it allows significant reduction or elimination of topical corticosteroid use: patients who have experienced adverse effects from prolonged steroid application (skin atrophy, striae, rebound flares) or who are concerned about steroid use on sensitive areas (face, eyelids, children's skin) often find XTRAC a viable alternative path. The treatment has no significant systemic side effects and is suitable for children as well as adults, making it relevant for paediatric eczema in areas of the face or body where parents are reluctant to continue steroid application. Results — suppression of active lesions, reduction in itch and improvement in skin barrier — typically become evident within the first five to ten sessions and are maintained for months after the course is complete.